Clinical trial

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

NCT06034938

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO] Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2024-02-08

PhasePHASE2

Conditions

Hivunresolved

Interventions

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate 100 MG-300 MG-300 MG Oral Tablet [DELSTRIGO]DRUG

Sponsors & collaborators

University Hospital, Caenlead sponsor

Merck Sharp & Dohme LLCcollaborator

Mapped research locations

CaenFrance1 RouenFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06034938 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.